Condition
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease clinical trials that are recruiting, at sites in 5 countries (most in China (2), Czechia (1), Germany (1)). By phase: Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 5Countries
Newest Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Observational study on CNS inflammatory demyelinating diseases in the Chinese population | — | Guangzhou, Guangdong | Recruiting | Aug 7, 2024 |
| Using Calculus Bovis Sativus to treat inflammatory demyelinating diseases | — | Wuhan, Hubei | Recruiting | Jun 25, 2024 |
| AI-assisted care for Multiple Sclerosis | — | Prague, Praha 2 and 2 other locations | Recruiting | Feb 28, 2024 |
| Comparing immediate and delayed treatments for children with anti-MOG antibody-related acute demyelinating syndromes | Phase 3 | Besançon and 8 other locations | Recruiting | Sep 19, 2022 |
| Investigating risk factors for disability progression in Multiple Sclerosis | — | Los Angeles, California | Recruiting | Jan 24, 2022 |
All recruiting trials (5)
-
Observational study on CNS inflammatory demyelinating diseases in the Chinese population
This study is looking to understand how certain brain diseases, like Multiple Sclerosis, affect people in China and what factors might influence their progression and treatment.
-
Using Calculus Bovis Sativus to treat inflammatory demyelinating diseases
This study is testing if a traditional Chinese medicine called Calculus Bovis Sativus can help people with conditions like multiple sclerosis feel better and reduce inflammation.
-
AI-assisted care for Multiple Sclerosis
This study is testing whether using AI can help doctors better diagnose and treat people with Multiple Sclerosis by analyzing real-world data.
-
Comparing immediate and delayed treatments for children with anti-MOG antibody-related acute demyelinating syndromes
This study is testing whether starting treatment right away with Azathioprine or Rituximab can help children with anti-MOG antibody-related acute demyelinating syndromes do better in the long run compared to waiting for treatment.
-
Investigating risk factors for disability progression in Multiple Sclerosis
This study is trying to find out what factors might make disability get worse in people with Multiple Sclerosis by looking at their medical history and MRI scans.
Related topics
Quick answers
How many Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in China (2 trials), Czechia (1 trial), Germany (1 trial), France (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.